2013-02-21 13:46:43 -
As previously communicated, the Board of Directors of Swedish Orphan Biovitrum
AB (Sobi) has decided to issue additional amounts the current bond loan with a
loan frame of SEK 1 billion. The issuance of SEK 200 million in nominal amount
is now fully subscribed.
Nordea Bank is acting as financial advisor to Sobi and Sole Bookrunner in
conjunction with the issuance.
For further information, please contact:
Investor Relations: Jörgen Winroth
Phone: +46-(0)8-697 20 00
About Swedish Orphan Biovitrum AB (Sobi)
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and neonatology. We also market
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 480 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.
The above information has been made public in accordance with Swedish Securities
Market Act and/or the Swedish Financial Instruments Trading Act. The information
was released for public distribution on 21 February 2013 at13.40 CET.
Sobi Press Release on February 21, 2013, in PDF format:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE